{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:45:09Z","timestamp":1790019909231,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00296-020-04732-z","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T16:43:35Z","timestamp":1603817015000},"page":"121-128","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Tocilizumab therapy in juvenile systemic sclerosis: a retrospective single centre pilot study"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2400-6955","authenticated-orcid":false,"given":"Amra","family":"Adrovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7834-4909","authenticated-orcid":false,"given":"Mehmet","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6963-9668","authenticated-orcid":false,"given":"Fatih","family":"Haslak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0101-9585","authenticated-orcid":false,"given":"Oya","family":"Koker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8046-3907","authenticated-orcid":false,"given":"Ayten","family":"Aliyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5365-3457","authenticated-orcid":false,"given":"Sezgin","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8459-2872","authenticated-orcid":false,"given":"Kenan","family":"Barut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-7720","authenticated-orcid":false,"given":"Ozgur","family":"Kasapcopur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,27]]},"reference":[{"key":"4732_CR1","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.berh.2018.02.004","volume":"31","author":"F Zulian","year":"2017","unstructured":"Zulian F (2017) Scleroderma in children. Best Pract Res Clin Rheumatol 31:576\u2013595","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"4732_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11926-014-0491-y","volume":"17","author":"I Foeldvari","year":"2015","unstructured":"Foeldvari I (2015) Update on juvenile systemic sclerosis. Curr Rheumatol Rep 17:18","journal-title":"Curr Rheumatol Rep"},{"key":"4732_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2174\/1573397114666180423105056","volume":"14","author":"A Adrovic","year":"2018","unstructured":"Adrovic A, Sahin S, Barut K, Kasapcopur O (2018) Juvenile Scleroderma\u2014what has changed in the meantime? Curr Rheumatol Rev 14:219\u2013225","journal-title":"Curr Rheumatol Rev"},{"key":"4732_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/2397198318790494","volume":"4","author":"I Foeldvari","year":"2018","unstructured":"Foeldvari I, Klotsche J, Torok SK et al (2018) Are diffuse and limited juvenile systemic sclerosis different in clinical presentation? clinical characteristics of a juvenile systemic sclerosis cohort. J Scleroderma Relat Disord 4:49\u201361","journal-title":"J Scleroderma Relat Disord"},{"key":"4732_CR5","doi-asserted-by":"publisher","first-page":"344","DOI":"10.5606\/ArchRheumatol.2018.6578","volume":"33","author":"A Adrovic","year":"2018","unstructured":"Adrovic A, \u015eahin S, Barut K, Kasap\u00e7opur \u00d6 (2018) Juvenile scleroderma: a referral center experience. Arch Rheumatol 33:344\u2013351","journal-title":"Arch Rheumatol"},{"key":"4732_CR6","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s00296-017-3793-3","volume":"37","author":"NK Bagri","year":"2017","unstructured":"Bagri NK, Raj D, Kaur J et al (2017) Juvenile systemic sclerosis: experience from a tertiary care center from India. Rheumatol Int 37:1687\u20131691","journal-title":"Rheumatol Int"},{"issue":"8","key":"4732_CR7","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s10067-006-0483-z","volume":"26","author":"R Misra","year":"2007","unstructured":"Misra R, Singh G, Aggarwal P, Aggarwal A (2007) Juvenile onset systemic sclerosis: a single center experience of 23 cases from Asia. Clin Rheumatol 26(8):1259\u20131262","journal-title":"Clin Rheumatol"},{"key":"4732_CR8","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.pcl.2018.04.002","volume":"65","author":"SC Li","year":"2018","unstructured":"Li SC (2018) Scleroderma in children and adolescents: localized scleroderma and systemic sclerosis. Pediatr Clin North Am 65:757\u2013781","journal-title":"Pediatr Clin North Am"},{"key":"4732_CR9","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1007\/s00296-020-04658-6","volume":"40","author":"B Doskaliuk","year":"2020","unstructured":"Doskaliuk B, Zaiats L, Yatsyshyn R et al (2020) Pulmonary involvement in systemic sclerosis: exploring cellular, genetic and epigenetic mechanisms. Rheumatol Int 40:1555\u20131569","journal-title":"Rheumatol Int"},{"key":"4732_CR10","doi-asserted-by":"crossref","first-page":"213e8","DOI":"10.1002\/art.27489","volume":"62","author":"AL Herrick","year":"2010","unstructured":"Herrick AL, Ennis H, Bhushan M, Silman AJ, Baildam EM (2010) Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. Arthritis Care Res 62:213e8","journal-title":"Arthritis Care Res"},{"key":"4732_CR11","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.rdc.2013.05.003","volume":"39","author":"I Foeldvari","year":"2013","unstructured":"Foeldvari I (2013) New developments in juvenile systemic and localized scleroderma. Rheumatol Dis Clin North Am 39:905\u2013920","journal-title":"Rheumatol Dis Clin North Am"},{"key":"4732_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/1744666X.2017.1243467","volume":"13","author":"F Zulian","year":"2017","unstructured":"Zulian F, Balzarin M, Birolo C (2017) Recent advances in the management of juvenile systemic sclerosis. Expert Rev Clin Immunol 13:361\u2013369","journal-title":"Expert Rev Clin Immunol"},{"key":"4732_CR13","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76:1327\u20131339","journal-title":"Ann Rheum Dis"},{"key":"4732_CR14","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/rheumatology\/kei211","volume":"45","author":"SN Liossis","year":"2006","unstructured":"Liossis SN, Bounas A, Andonopoulos AP (2006) Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology 45:1005\u20131008","journal-title":"Rheumatology"},{"key":"4732_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/art.1780350111","volume":"35","author":"BW Needleman","year":"1992","unstructured":"Needleman BW, Wigley FM, Stair RW (1992) Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheumatol 35:67\u201372","journal-title":"Arthritis Rheumatol"},{"key":"4732_CR16","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1080\/14397595.2018.1559909","volume":"29","author":"Y Shima","year":"2019","unstructured":"Shima Y (2019) The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis. Mod Rheumatol 29:294\u2013330","journal-title":"Mod Rheumatol"},{"key":"4732_CR17","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00296-020-04515-6","volume":"40","author":"DP Misra","year":"2020","unstructured":"Misra DP, Ahmed S, Agarwal V (2020) Is biological therapy in systemic sclerosis the answer? Rheumatol Int 40:679\u2013694","journal-title":"Rheumatol Int"},{"key":"4732_CR18","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1136\/annrheumdis-2012-202657","volume":"72","author":"M Elhai","year":"2013","unstructured":"Elhai M, Meunier M, Matucci-Cerinic M et al (2013) Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis 72:1217\u20131220","journal-title":"Ann Rheum Dis"},{"key":"4732_CR19","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","volume":"77","author":"D Khanna","year":"2018","unstructured":"Khanna D, Denton CP, Lin CJF et al (2018) 2018) Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (fascinate). Ann Rheum Dis 77:212\u2013220","journal-title":"Ann Rheum Dis"},{"key":"4732_CR20","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Jahreis A et al (2016) Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (fascinate): a phase 2, randomised, controlled trial. Lancet 387:2630\u20132640","journal-title":"Lancet"},{"key":"4732_CR21","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.berh.2019.01.011","volume":"32","author":"G Zacay","year":"2018","unstructured":"Zacay G, Levy Y (2018) Outcome of patients with systemic sclerosis treated with tocilizumab: case series and review of the literature. Best Pract Res Clin Rheumatol 32:563\u2013571","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"4732_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1080\/14397595.2018.1452178","volume":"29","author":"Y Shima","year":"2019","unstructured":"Shima Y, Kawaguchi Y, Kuwana M (2019) Add-on tocilizumab versus conventional treatment for systemic sclerosis, and cytokine analysis to identify an endotype to tocilizumab therapy. Mod Rheumatol 29:134\u2013139","journal-title":"Mod Rheumatol"},{"key":"4732_CR23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40272-020-00382-7","volume":"22","author":"ZH Temrikar","year":"2020","unstructured":"Temrikar ZH, Suryawanshi S, Meibohm B (2020) Pharmacokinetics and clinical pharmacology of monoclonal antibodies in pediatric patients. Paediatr Drugs 22:199\u2013216","journal-title":"Paediatr Drugs"},{"key":"4732_CR24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/art.22551","volume":"57","author":"F Zulian","year":"2007","unstructured":"Zulian F, Woo P, Athreya BH et al (2007) The Pediatric Rheumatology European Society\/American College of Rheumatology\/European League against rheumatism provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheumatol 57:203\u2013212","journal-title":"Arthritis Rheumatol"},{"key":"4732_CR25","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1002\/art.34652","volume":"64","author":"F La Torre","year":"2012","unstructured":"La Torre F, Martini G, Russo R et al (2012) A preliminary disease severity score for juvenile systemic sclerosis. Arthritis Rheumatol 64:4143\u20134150","journal-title":"Arthritis Rheumatol"},{"key":"4732_CR26","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.rdc.2013.02.017","volume":"39","author":"R Chapin","year":"2013","unstructured":"Chapin R, Hant FN (2013) Imaging of scleroderma. Rheum Dis Clin North Am 39:515\u2013546","journal-title":"Rheum Dis Clin North Am"},{"key":"4732_CR27","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/rheumatology\/kex382","volume":"57","author":"H Lythgoe","year":"2018","unstructured":"Lythgoe H, Baildam E, Beresford MW, Cleary G, McCann LJ, Pain CE (2018) Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma. Rheumatology 57:398\u2013401","journal-title":"Rheumatology"},{"key":"4732_CR28","first-page":"S1699-258X(18)3","volume":"pii","author":"M Osminina","year":"2018","unstructured":"Osminina M, Geppe N, Afonina E (2018) Scleroderma \u201cen coup de sabre\u201d with epilepsy and uveitis successfully treated with tocilizumab. Rheumatol Clin pii:S1699-258X(18)30113-X","journal-title":"Rheumatol Clin"},{"key":"4732_CR29","first-page":"211","volume":"35","author":"G Martini","year":"2017","unstructured":"Martini G, Campus S, Raffeiner B, Boscarol G, Meneghel A, Zulian F (2017) Tocilizumab in two children with pansclerotic morphoea: a hopeful therapy for refractory cases? Clin Expert Rheumatol 35:211\u2013213","journal-title":"Clin Expert Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-020-04732-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-020-04732-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-020-04732-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T03:01:19Z","timestamp":1698289279000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-020-04732-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,27]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["4732"],"URL":"https:\/\/doi.org\/10.1007\/s00296-020-04732-z","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,27]]},"assertion":[{"value":"12 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standard"}},{"value":"All the authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Ethics Committee of the Istanbul University-Cerrahpasa Institutional Review Board (83045809\/604.01), has approved the study. The investigation has been performed in accordance with the ethical standards laid down in Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subject. All the \u201cPrinciples of laboratory animal care\u201d were followed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}